Biocon Limited Concludes Rs 4,150 Crore (~USD 460 million) Equity Fundraise through a Ǫualified Institutions Placement (ǪIP)

Bengaluru, Karnataka, India: January 14, 2026:

Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceutical company, today announced the successful completion of a Ǫualified Institutions Placement (ǪIP), raising Rs 4,150 crore (~USD 460 million) through the issuance of 112,664,585 equity shares of face value Rs 5 each to eligible qualified institutional buyers at the issue price of Rs 368.35 per Equity Share (including a premium of Rs 363.35 per Equity Share).

The ǪIP, which opened on January 12, 2026, and closed on January 14, 2026, attracted strong investor interest from a broad mix of domestic and international participants, reflecting robust confidence in Biocon’s growth prospects.

The proceeds from the ǪIP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited, including repayment of debt availed in this regard. Biocon recently announced that its Board of Directors had approved a strategic corporate action to acquire all remaining minority shareholdings, including Viatris’ stake, thereby making Biocon Biologics a wholly owned subsidiary of the Company.

This integration marks a pivotal step in Biocon’s journey to lead in the therapeutic areas of diabetes, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, generics and peptides (GLP-1s). The integration process is expected to be completed no later than March 31, 2026.

Key Transaction Highlights:

• ǪIP saw healthy interest from all pools of capital across Domestic Mutual Funds (“MFs”), Domestic Insurance Companies, and Foreign Institutional Investors (“FIIs”) – highlighting investor’s confidence in Biocon’s differentiated business model and growth potential of the combined business.
• Witnessed interest from 39 investors and allocations to all 39 investors.
• Robust participation from leading financial institutions including SBI Mutual Fund, ICICI Prudential Mutual Fund, Mirae Asset Mutual Fund, Birla Mutual Fund, HDFC Life Insurance, ICICI Prudential Life Insurance, JPMorgan Asset Management, among others.

The net proceeds from the ǪIP will be utilized for:

• Payment of cash consideration to Mylan Inc. (Viatris) for acquisition of shares of Biocon Biologics Limited, including repayment of debt availed in this regard.
• Re-payment of debt availed, for the acquisition of compulsory convertible debentures (CCDs) of Biocon Biologics Limited, held by Edelweiss.
• General corporate purposes.

The Company received shareholders’ approval for the fundraise at the Extra-Ordinary General Meeting held on December 31, 2025.

Book Running Lead Managers and Legal Counsels: Kotak Mahindra Capital Company Limited, HSBC Securities and Capital Markets (India) Private Limited, J.P. Morgan India Private Limited and Morgan Stanley India Company Private Limited acted as Book Running Lead Managers to the ǪIP. Shardul Amarchand Mangaldas C Co. was the Legal Counsel to the Company while Linklaters Singapore Pte. Ltd. and JSA Advocates C Solicitors were the Legal Counsels to the Book Running Lead Managers.

About Biocon Limited

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceutical company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the U.S., Europe C key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com Follow-us on X (formerly Twitter) @bioconlimited and LinkedIn: @BioconLimited for company updates. For FY25 Integrated Annual Report of Biocon click here

Biocon Biologics Limited, a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its ‘lab to market’ capabilities to serve over 6.3 million patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. Biocon Biologics has commercialized 10 biosimilars from its portfolio which are addressing the patients’ needs in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 20+ biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other non- communicable diseases. The Company has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website: www.bioconbiologics.com; Follow us on X (formerly Twitter): @BioconBiologics and LinkedIn: Biocon Biologics for company updates.